Arvaya Healthcare Limited revises Rights Issue committee authorisation details
Bijoy Hans · Commercial Services & Supplies
Key highlights
- Board meeting held on 4th November 2026; earlier outcome dated 4th November revised
- Rights Issue Committee authorised to finalise Draft Letter of Offer for ₹210 crore partly paid-up equity shares
- Committee to file DLOF with BSE and decide final issue terms including price and record date
Why it's rated notable: the amount is 37% of market value (20% to 50%)
Original filing
Revised Outcome For Board Meeting Dated 04 November 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Bijoy Hans
- Fundraise / allotmentNotableArvaya Healthcare Limited proposes Rights Issue of Equity Shares up to ₹210 Cr
- Acquisition / mergerNotableArvaya Healthcare Limited completes acquisition of 100% equity of SIGPL
Other fundraise / allotment filings this fortnight
- Gujarat Inject (Kerala) approves Q2 and H1 standalone results to 30 Sep 2026
- Flywings Simulator Training Centre seeks approval for 29,87,760 warrants at ₹245
- Flywings Simulator Training Centre approves preferential issue of 29,87,760 warrants
- Rashi Peripherals Limited announces Board decisions and share issuance proposal
- Rashi Peripherals announces Board changes, share sale, and equity issuance plans
- Rashi Peripherals Limited approves several corporate actions and appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Commercial Services & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.